Xeris Biopharma Holdings, Inc. (XERS) stock
XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.99+0.19 (+1.13%)
Close on Nov 18, 2026Market cap $3.10BP/E –Yield –
Xeris Biopharma cash
Cash and short-term investments held at the end of each period.
Xeris Biopharma's cash was $121.75M at Jun 30, 2026. For fiscal 2025 it was $111.04M, up 46.6% from the year before. The highest annual figure on record is $133.79M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $111.04M | +46.6% |
| FY2024 | Dec 31, 2024 | $75.74M | +4.5% |
| FY2023 | Dec 31, 2023 | $72.45M | -42.6% |
| FY2022 | Dec 31, 2022 | $126.31M | +23.3% |
| FY2021 | Dec 31, 2021 | $102.43M | -23.4% |
| FY2020 | Dec 31, 2020 | $133.79M | +585.4% |
| FY2019 | Dec 31, 2019 | $19.52M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $121.75M | +105.4% |
| Q1 FY2026 | Mar 31, 2026 | $111.75M | +91.2% |
| Q4 FY2025 | Dec 31, 2025 | $111.04M | +46.6% |
| Q3 FY2025 | Sep 30, 2025 | $91.60M | +32.0% |
| Q2 FY2025 | Jun 30, 2025 | $59.29M | -23.6% |
| Q1 FY2025 | Mar 31, 2025 | $58.44M | -33.1% |
| Q4 FY2024 | Dec 31, 2024 | $75.74M | +4.5% |
| Q3 FY2024 | Sep 30, 2024 | $69.40M | +5.2% |
| Q2 FY2024 | Jun 30, 2024 | $77.57M | -3.8% |
| Q1 FY2024 | Mar 31, 2024 | $87.35M | -8.1% |
| Q4 FY2023 | Dec 31, 2023 | $72.45M | -42.6% |
| Q3 FY2023 | Sep 30, 2023 | $65.98M | -29.4% |
| Q2 FY2023 | Jun 30, 2023 | $80.67M | -27.7% |
| Q1 FY2023 | Mar 31, 2023 | $95.10M | -28.0% |
| Q4 FY2022 | Dec 31, 2022 | $126.31M | +23.3% |
| Q3 FY2022 | Sep 30, 2022 | $93.43M | +0.5% |
| Q2 FY2022 | Jun 30, 2022 | $111.55M | +75.4% |
| Q1 FY2022 | Mar 31, 2022 | $132.15M | +98.4% |
| Q4 FY2021 | Dec 31, 2021 | $102.43M | -23.4% |
| Q3 FY2021 | Sep 30, 2021 | $92.98M | +145.4% |
| Q2 FY2021 | Jun 30, 2021 | $63.60M | +225.8% |
| Q1 FY2021 | Mar 31, 2021 | $66.60M | – |
| Q4 FY2020 | Dec 31, 2020 | $133.79M | – |
| Q3 FY2020 | Sep 30, 2020 | $37.89M | – |
| Q4 FY2019 | Dec 31, 2019 | $19.52M | – |
See a number that looks wrong?